Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium

International Journal of Urology

Volumn 11, Issue 7, 2004, Pages 461-466

  Hoschke, Bernd ^a,b   May, Matthias ^a   Seehafer, Matthias ^a   Helke, Christian ^a  

^a Carl Thiem Hospital   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carboplatin; Gemcitabine; Metastasis; Transitional cell carcinoma

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; AGE; AGED; ALOPECIA; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSCIOUSNESS DISORDER; CREATININE CLEARANCE; DRUG SAFETY; EDEMA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LETHARGY; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; URINARY TRACT CARCINOMA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 4043067876     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0919-8172.2004.00846.x     Document Type: Article

References (19)

1. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA. Familial aggregation of urothelial cell carcinoma. Int. J. Cancer 2002; 98: 274-8.
2. de Braud F, Maffezzini M, Vitale V et al. Bladder cancer. Crit. Rev. Oncol. Hematol. 2002; 41: 89-106.
3. von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Semin. Oncol. 2002; 29 (Suppl. 3): 3-14.
4. Sternberg CN. Gemcitabine in bladder cancer. Semin. Oncol. 2000; 27 (Suppl. 2): 31-9.
5. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 1985; 133: 403-7.
6. Loehrer PJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 1992; 10: 1066-73.
7. Prout GR, Kaufman DS. The National Bladder Cancer Group's experience: invasive and metastatic bladder cancer selected reports. Semin. Urol. Oncol. 2001; 19: 66-8.
8. Stadler WM. Gemcitabine doublets in advanced urothelial cancer. Semin. Oncol. 2002; 29 (Suppl. 3): 15-19.
9. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-77.
10. Akaza H. Developing therapies for advanced bladder cancer. Expert Opin. Invest. Drugs 2002; 11: 109-15.
11. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clustering gene in a human bladder cancer model. Clin. Cancer Res. 2001; 7: 4245-52.
12. Carles J, Nogue M. Gemcitabine/carboplatin in advanced urothelial cancer. Semin. Oncol. 2001; 28 (Suppl. 10): 19-24.
13. Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann. Oncol. 2001; 12: 947-52.
14. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer 1998; 34: 1208-12.
15. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol. 1997; 15: 3441-5.
16. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 1997; 15: 3394-8.
17. Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur. J. Cancer 2001; 37: 2212-15.
18. Chatelut E, Pivot X, Otto J et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur. J. Cancer 2000; 36: 264-9.
19. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77: 344-51.